Lancet Oncology reports safety and efficacy of Holmium-166 SIRT after PRRT

Published by admin on

Terumo Europe N.V. and Quirem Medical B.V are proud to share the latest key publication regarding holmium-166 (QuiremSpheres®) Selective Internal Radiation Therapy (SIRT). On 27 February 2020, the UMC Utrecht published their latest results in the Lancet Oncology Journal from the non-randomized HEPAR PLuS study. The study enrolled neuroendocrine tumor (NET) patients with liver disease for Holmium-166 SIRT after successful completion of 4 cycles of Peptide Receptor Radionuclide Therapy (PRRT).
From data published on PRRT, it is known that NET patients with larger liver metastases have less favorable survival outcomes after PRRT. In this study, it was investigated whether additional treatment of liver metastases using Holmium-166 SIRT improves the response rates for this group of patients.

HEPAR PLuS proved that the additional radiation boost provided by Holmium-166 SIRT following PRRT resulted in a high liver objective response rate of 43 % and 47% after 3 and 6 months.

“By boosting treatment of liver disease with Holmium-166 SIRT in NET patients after PRRT, we expect to improve both overall survival and quality of life with a relatively well-tolerated therapy. This publication shows that we indeed see an additional tumor response in the liver,” first author Dr. Arthur Braat comments.

“This is an important next step to show the importance of Holmium-166 SIRT in treating mNET patients by combining it with other treatment modalities such as PRRT.” said Rijk de Jong, Medical Director of Quirem Medical. “We also believe that the individualized treatment planning approach of Holmium SIRT will further translate into enhanced efficacy and safety for the benefit of patients undergoing SIRT procedures.”

“This is a very exciting milestone for QuiremSpheres® and the next step in building the future for SIRT.” added Peter Coenen, President of Terumo Interventional Systems EMEA. “This publication further validates the importance of Holmium-166 SIRT and the individualized treatment planning you can perform when using Holmium SIRT. We at Terumo believe is a vital step to advance patient selection and optimize dosimetry to achieve better outcomes for mNET patients and liver cancer patients in general”.

Holmium-166 SIRT is the only SIRT technology that uses the same microspheres for the work-up (QuiremScout®) and treatment (QuiremSpheres®), which aims to optimize patient selection and advance treatment planning.

 

The full text of the publication can be found here on the Lancet Oncology website.

 

[1] J Strosberg et. al ;. J CLIN ONCOL 2016

[1] J Strosberg, et al. Ann Oncol. 2018;29(Suppl8): Abstract 1316P

Categories: News